Grünenthal
Tracked across 4 events · 34 articles · First seen Jun 29, 2026 · Last active Sep 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Grünenthal successfully completed a Phase I trial for its NOP agonist, demonstrating its safety and tolerability. This positive development allows the company to advance the compound to Phase II trials, potentially leading to a new pain treatment option and enhancing Grünenthal's market position in pain management.
Jun 29, 2026 · 9 articles
Regulatory
Impact: Grünenthal received FDA designations for its investigational drug tegacorat, a positive regulatory milestone that may enhance its pipeline value and future revenue prospects.
Jul 08, 2026 · 10 articles
Business
Impact: Grünenthal is the main actor, joining CNATM to enhance its oligonucleotide capabilities for pain and neurological diseases. This strengthens its R&D pipeline in genetic medicine.
Jul 16, 2026 · 9 articles
Business
Grunenthal, a privately held German pharmaceutical company focused on pain management, announced an agreement with Bayer to acquire the cancer treatment Stivarga (regorafenib) for up to 375 million euros. Stivarga is an oral multikinase inhibitor…
Impact: Grunenthal is the acquirer of Stivarga, paying up to 375 million euros to expand its established medicines portfolio. The deal is expected to be immediately accretive and add up to about 100 million euros to EBITDA by 2027.
Sep 21, 2026 · 6 articles
95
Grünenthal acquired BayerGrunenthal Acquires Bayer...
20
Grünenthal acquired full ownership Kyowa KirinGrunenthal Acquires Bayer...
ERGEN INTELLIGENCE
Track Grünenthal live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard